Articles tagged with Melanoma
A team from UNIGE and HUG identified a protein regulation mechanism that reduces melanoma cells' capacity to adapt and resist treatment. They found that targeting this mechanism with an enzyme inhibitor reduces therapeutic resistance in all melanoma cells.
Tel Aviv University researchers discovered that skin cancer cells interact with astrocytes in the brain, promoting metastasis. By inhibiting this interaction using existing treatments, they delayed the spread of melanoma to the brain by 60-80%. This breakthrough has implications for treating advanced-stage melanoma.
Researchers found mutations in leukocyte and T-cell proliferation regulation processes that contribute to ICI treatment response and resistance. The study provides a framework to develop predictors for melanoma, potentially enhancing responses and increasing patient numbers.
Researchers found that ruxolitinib, a clinically approved drug, suppresses ICB-resistant melanomas by reprogramming TILs and relying on host TNF signaling. This discovery offers a potential target for bypassing therapeutic resistance in advanced melanoma patients.
Researchers found that starting pembrolizumab before surgery significantly improves the outlook for patients with stage III-IV melanoma. The study showed a 42% lower event rate in patients receiving neoadjuvant therapy compared to those receiving adjuvant therapy.
A phase 3 study shows that tumour-infiltrating lymphocytes (TIL) therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma. The treatment reduces disease progression or death by 50% in patients treated with TILs.
A new study by Emory University researchers suggests that antibiotics can accelerate the growth of malignant melanoma in mice by depleting their intestinal flora and weakening their immune response. This depletion leads to a higher tumor burden in infected mice compared to those with intact gut microbiomes.
Researchers from the University of Queensland are conducting a three-year project to combat melanoma, focusing on stopping its progression to the brain and investigating its seeding in a neural environment. The team aims to develop new therapies to improve treatment outcomes for affected US troops and Australians.
A recent study has found that vitamin D deficiency is associated with lower overall survival rates in melanoma patients. The research, presented at the European Academy of Dermatology and Venereology Congress, suggests that vitamin D levels play a significant role in determining patient outcomes.
Researchers discovered a small molecule Gαq/11 protein inhibitor, GQ262, that effectively combats uveal melanoma by targeting Gαq/11 directly. In vitro and in vivo studies demonstrated its ability to induce apoptosis and disrupt downstream effectors.
Researchers at Sanford Burnham Prebys have shown that inhibiting a key metabolic enzyme selectively kills melanoma cells and stops tumor growth. The study identifies GCDH as the crucial enzyme in metabolizing lysine and tryptophan, amino acids essential for human health.
Researchers identified high-risk patients with stage 3A disease and microscopic lymph node metastases who would benefit from adjuvant therapy. Patients with larger metastases had poorer outcomes, while those with smaller metastases had better survival rates similar to stage 1A disease.
Researchers at the Centre for Genomic Regulation have identified PDIA6 as a key protein involved in driving melanoma malignancy. The study found that PDIA6 promotes melanoma cell growth by binding to RNA molecules inside tumor cells, making it a promising therapeutic target.
Researchers at TIBI developed a minimally invasive method for targeted delivery of immunotherapeutic treatments, resulting in slower tumor growth and higher activation of T-cells. The injectable gelatin biomaterial containing silicate nanoplatelets showed sustained drug release and controlled ICI delivery.
A new combination of nanoparticles and a vaccine has been developed to target melanoma. In experiments using mice, this combination eliminated cancerous tumors or extended survival rates.
Researchers from the University of Gothenburg found that assessing melanoma thickness is challenging for both human dermatologists and machine-learning algorithms. Despite differences in success rates, both groups achieved comparable results when evaluating dermoscopic images, highlighting the need for further study to improve diagnost...
Researchers uncovered details about the underlying biology of melanoma brain metastases, including genomics, immunology, and spatial organization. The study found that melanoma brain metastases are more chromosomally unstable than other types of metastases, with potential therapeutic targets in reduced chromosomal instability.
Researchers identify key features of a gene mutation responsible for 15-20% of melanomas, establishing a link between the frequency of specific NRAS mutations and spontaneous melanoma formation. The study could help pinpoint early events required for melanoma formation and develop targeted treatments.
A new combination therapy using a plant virus and an antibody activates natural killer cells to target and destroy cancer cells. The therapy eliminates all tumors and prevents their recurrence, resulting in 100% survival in mouse models of colon cancer.
Researchers found higher AR signaling and better response rates for female patients treated with BRAF/MEK inhibitors. Blocking the AR improved response to BRAF/MEK targeted therapy in both males and females.
A newly developed small-molecular radiopharmaceutical pair has successfully visualized and treated melanoma in a preclinical study. The theranostic approach targets metabotropic glutamate receptor 1 (GRM1) found in many human solid tumors.
A novel BRAF inhibitor, C1a, has been developed to cross the blood-brain barrier and treat melanoma brain metastasis. The study found that C1a triggered robust responses in patient-derived models and outperformed approved BRAF inhibitors, achieving significant increases in survival rates.
A large US study has found an association between higher fish consumption and increased risk of malignant melanoma and stage 0 melanoma. The study found that eating more non-fried fish and tuna was linked to a greater risk of developing these types of skin cancer.
MD Anderson research highlights new treatments for skin cancers, including novel therapies. The institution also showcased improved goals of care programs, which demonstrated significant reductions in ICU mortality and improved patient outcomes during the COVID-19 pandemic.
Researchers found that neoadjuvant immunotherapy with pembrolizumab significantly shrunk tumors in patients with desmoplastic melanoma, potentially allowing for less extensive surgery and radiation. The study showed a high response rate to treatment, with over half of patients achieving a pathologic complete response.
A Brazilian group developed a peptide called Rb4 that triggers necrosis in murine melanoma cells and inhibits the viability of human cancer cells. In mice, Rb4 reduced lung metastasis and slowed subcutaneous melanoma growth, increasing survival by 25%.
A new study aims to assess the effectiveness of sun safety policies in primary schools in Wales. The project will examine what is currently being taught about sun safety and its impact on knowledge and behavior among children, teachers, staff, and school managers.
Recent studies found that pathologists perceive an overdiagnosis of melanoma, with many diagnosing cases as non-invasive melanoma despite variability in diagnoses. A study involving over 100 dermatopathologists showed a majority agree on the issue, but awareness may not be enough to reduce overdiagnosis.
Researchers at Harvard Medical School have created spatial maps that show how melanoma cells and immune cells interact as a tumor develops. The maps, which offer insights into the early events in melanoma, reveal signs of immunosuppression and may aid in understanding how to prevent or treat the disease.
New research found that 62% of tinted sunscreens have only one shade option, with tone compatibility being the most important criterion. The study suggests that the beauty industry and dermatologic field need to improve diversity and offer more options for tinted sunscreen formulations tailored to people with skin of color.
Researchers have identified a gene mutation in ARID2 that signals the development of aggressively metastatic melanoma. The study suggests patients with this mutation may require different treatment approaches to manage their cancer effectively. Further research is underway to refine this understanding and improve patient outcomes.
Levi A. Garraway is being honored for his groundbreaking contributions to cancer research, including the identification of melanoma genes and development of precision oncology approaches. He has also championed parallel sequencing as a definitive approach to tumor genomic profiling, revolutionizing cancer treatment strategies.
The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.
Researchers from H. Lee Moffitt Cancer Center identified unique features of acral melanoma, including immune checkpoints that could represent novel therapeutic targets for this neglected disease. The study's findings may lead to more effective treatments for patients with acral melanoma.
Researchers found that patients with stage III melanoma who received immunotherapy alone had better rates of distant metastasis-free survival compared to those who underwent completion lymph node dissection. The study suggests that de-escalation of unnecessary therapies, such as CLND, may improve patient outcomes and reduce complications.
Melanoma referral centers worldwide have adopted systemic therapies to treat high-risk melanoma, reducing the need for lymph node removal surgeries. The shift in treatment plans was driven by rapid adoption of effective treatments and a desire to avoid lifelong complications of surgery.
A team of researchers has discovered blood biomarkers that can predict patient response to immunotherapy treatment for melanoma. The study found that patients with increased lactate levels and specific lipid and amino acid metabolites were more likely to respond to treatment.
A pioneering test called AMBLor has been developed to predict the spread or return of skin cancer. By analyzing primary tumor biopsies, the test identifies patients at low risk of disease progression, providing them with more accurate information and personalized prognosis.
The combination of relatlimab and nivolumab doubled progression-free survival benefit compared to nivolumab alone, with significant benefits across pre-specified subgroups. The treatment was associated with a lower risk of disease progression or death.
Patients with sufficient fiber intake had improved progression-free survival and response to immunotherapy in melanoma. A high-fiber diet was associated with slower tumor growth and increased CD4+ T cells in pre-clinical models, supporting the potential benefits of dietary interventions on cancer treatment outcomes.
A research team has identified a bacterium responsible for producing palmerolide A, a melanoma-fighting compound found in Antarctic sea squirts. The discovery could lead to the development of naturally-derived treatments for skin cancer.
CNIO researchers have identified a new biomarker for early melanoma metastasis, proposing the use of NGFR to predict disease prognosis and define risk groups. Blocking NGFR drastically reduces metastasis in mice, paving the way for a potential first treatment to tackle metastasis in its earliest stages.
The CDI laboratory has identified a complex natural pathway that melanoma hijacks to metastasize. The pathway centers around the silencing of bone morphogenetic protein 6 (BMP6), leading to abnormal cell signaling and increased cancer cell motility.
A clinical trial found that giving immunotherapy before targeted therapy improves survival in advanced melanoma patients, with a two-year overall survival rate of 72% compared to 52%. The study suggests that immunotherapy should be the initial approach for treating metastatic melanoma patients, regardless of BRAF mutation status.
A Phase II study shows that combination treatment with nivolumab and ipilimumab improves overall survival in patients with asymptomatic melanoma brain metastases, with an overall survival rate of 71.9% at three years. The treatment demonstrates durable responses, even in symptomatic patients.
Researchers at West Virginia University have received FDA approval for a new drug to treat uveal melanoma, a rare form of eye cancer. The drug, MTI-201, targets specific biomarkers in diseased cells, allowing for more precise treatment with minimal damage to healthy cells.
Researchers found that melanomas detected during routine skin checks were associated with a significantly lower all-cause risk of death, but not melanoma-specific death. The study involved 2,452 patients in Australia and suggests a potential benefit to regular skin cancer screenings.
Metastases in malignant melanoma can use an alternative process to access the circulatory system, where a blood vessel divides into two parallel vessels. This finding challenges traditional research on tumor growth and may lead to new treatment options for metastatic cancer.
Researchers analyzed fecal metagenomic DNA sequencing data to see if specific donor strains correlated with successful treatment outcomes. They found no correlation between donor strains and response to anti-PD-1 therapy in melanoma patients.
Researchers discovered that adrenal gland metastases are unresponsive to checkpoint inhibitors due to the secretion of corticosteroids. Surgical removal is the current best course of action for patients with these metastases. The study's authors hope to develop a nonsurgical treatment option in the future.
The KEYNOTE-716 trial shows that adjuvant pembrolizumab significantly prolongs recurrence-free survival and halves distant recurrences in stage II B/C melanoma patients. This suggests that patients with high-risk stage II melanoma should be offered adjuvant therapy.
Researchers developed a treatment using cowpea mosaic virus nanoparticles that target lung tumors, slowing tumor growth and preventing cancer spread. The treatment showed efficacy against aggressive cancer cell lines and may offer protection to patients at high risk of metastatic disease.
A new combination treatment has shown significant tumor shrinkage and prolonged survival in patients with metastatic uveal melanoma. The treatment, which targets HDAC and PD-1 proteins, was found to work better in tumors with active BAP1 genes, a key discovery that may lead to improved survival rates.
Patients with relapsed metastatic melanoma who received prior anti-PD-1 therapies had a lower response rate to adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL). ACT-TIL was less effective in these patients compared to those who had never received anti-PD-1 therapy. The study found that the objective response rate and ...
Researchers developed a nanotherapeutic platform that combines camptothecin with immune checkpoint inhibitors to increase effectiveness against aggressive tumors. The approach showed promising results in eliminating difficult-to-treat late-stage metastatic colorectal cancer and melanoma tumors.
Researchers found that UVB radiation from the sun causes chemical changes to DNA, leading to disease-causing mutations. This discovery sheds light on the origins of melanoma and highlights the importance of prevention efforts.
A study found specific gut microbiota signatures correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment. The research identified a potential new strategy to treat toxicity while maintaining response through IL-1R inhibition or manipulation of the gut microbiota.
Researchers analyzed molecular analysis data from a pediatric melanoma registry, identifying diverse subgroups and their characteristics. The study found that spitzoid melanomas often have gene fusions and benign clinical courses, while conventional melanoma patients with advanced disease had poorer outcomes.
The partnership aims to reduce the risk of relapse in Stage 2 melanoma patients using BRAF and MEK targeted therapies. EORTC and Pierre Fabre will conduct a large Phase 3 study to advance research in melanoma.
A large clinical trial has shown that pembrolizumab after surgery significantly lowers the risk of disease recurrence in patients with high-risk melanoma. This treatment also results in fewer serious side effects compared to standard therapies like ipilimumab or high-dose interferon.